Why the study?
Does continuous subcutaneous insulin infusion improve vascular function and reduce glucose variability in children with type 1 diabetes compared to multiple daily injections?
Does continuous subcutaneous insulin infusion improve vascular function and reduce glucose variability in children with type 1 diabetes compared to multiple daily injections?
Initiation of CSII in children with type 1 diabetes transiently improves vascular function and glucose variability at 3 weeks, but these benefits are lost by 12 months as metabolic control deteriorates.
Answers are grounded in this paper and cite their sources.
CSII-linked vascular and glycemic gains in pediatric T1D fade by 12 months; hypothesis-generating for durability strategies before practice change.
OBJECTIVE: The effect of continuous subcutaneous insulin infusion (CSII) and glucose variability on vascular health in type 1 diabetes (T1D) is not known. We aimed to determine whether initiation of CSII improves vascular function and reduces glucose variability, independent of changes in HbA1c. METHODS: Twenty-two children with T1D (12.5 ± 2.9 yr) were reviewed immediately prior, 3 wk, and 12 months after initiation of CSII. Vascular function [flow-mediated dilatation (FMD), glyceryl trinitrate-mediated dilatation (GTN)], glucose variability [mean of daily differences (MODD), mean amplitude of glycaemic excursions (MAGE) and continuous overlapping net glycaemic action (CONGA)], and clinical and biochemical data were measured at each visit. Results for the first two visits were compared to a previously studied cohort of 31 children with T1D who remained on multiple daily injections (MDI). RESULTS: FMD, GTN, blood pressure, HbA1c, fructosamine, and glucose variability significantly improved 3 wk after CSII commencement (all p < 0.05), but there was no change in the MDI control group. At 3 wk, vascular function related to glucose variability [(FMD: MODD, r = -0.62, p = 0.002) and (GTN: MAGE, r = -0.59, p = 0.004; CONGA-4, r = -0.51, p = 0.01; MODD, r = -0.62, p = 0.002)] but not to blood pressure, HbA1c, or fructosamine. At 12 months, FMD, GTN, blood pressure, and glucose variability returned to baseline levels, while HbA1c deteriorated. Carotid intima media thickness was unchanged over 12 months. CONCLUSIONS: Initiation of CSII rapidly improves vascular function in association with decreased glucose variability; however, the effects are not sustained with deterioration of metabolic control and glucose variability.
No takes yet. Share an insight, caveat, or question.
Harrington et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: